Nektar Therapeutics Q2 2026 Earnings Report

Nektar Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.97
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Nektar Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $10.43 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Nektar Therapeutics Announcement Details

• Quarter: Q2 2026
• Date: 8/13/2026
• Time: After Market Closes
• Conference Call Date: Thursday, August 13, 2026
• Conference Call Time: 5:00PM ET

Nektar Therapeutics (NASDAQ:NKTR) (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs. Notable examples are NKTR-214 (bempegaldesleukin), an immuno-oncology agent designed to stimulate T-cell and natural killer cell activity in combination with checkpoint inhibitors, and NKTR-255, an IL-15 receptor agonist intended to enhance immune responses in oncology and infectious diseases. The company’s earlier polymer conjugate derivative of irinotecan, etirinotecan pegol, was licensed to a global partner for the treatment of metastatic breast cancer, underscoring Nektar’s expertise in drug delivery innovation.

Founded in 1990 and headquartered in San Francisco, Nektar operates research and development facilities in the United States and collaborates with international pharmaceutical companies to advance its pipeline. Its partnerships have included agreements with Bristol-Myers Squibb and AstraZeneca, reflecting a strategy of combining its novel molecules with established therapies to maximize patient benefit.

Under the leadership of President and Chief Executive Officer Howard W. Robin, Nektar continues to invest in its core technology platforms. The management team brings deep experience in biopharmaceutical development, clinical operations and global regulatory affairs, positioning the company to progress multiple candidates through clinical trials and toward potential regulatory approval.